These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 9166099)

  • 21. Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma.
    Prince HM; Duvic M; Martin A; Sterry W; Assaf C; Sun Y; Straus D; Acosta M; Negro-Vilar A
    J Clin Oncol; 2010 Apr; 28(11):1870-7. PubMed ID: 20212249
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunomodulatory effects of RXR rexinoids: modulation of high-affinity IL-2R expression enhances susceptibility to denileukin diftitox.
    Gorgun G; Foss F
    Blood; 2002 Aug; 100(4):1399-403. PubMed ID: 12149223
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase II study of denileukin diftitox for relapsed/refractory B-Cell non-Hodgkin's lymphoma.
    Dang NH; Hagemeister FB; Pro B; McLaughlin P; Romaguera JE; Jones D; Samuels B; Samaniego F; Younes A; Wang M; Goy A; Rodriguez MA; Walker PL; Arredondo Y; Tong AT; Fayad L
    J Clin Oncol; 2004 Oct; 22(20):4095-102. PubMed ID: 15353540
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting diphtheria toxin to growth factor receptors.
    Murphy JR; vanderSpek JC
    Semin Cancer Biol; 1995 Oct; 6(5):259-67. PubMed ID: 8562903
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase I trial of an interleukin-2 fusion toxin (DAB486IL-2) in hematologic malignancies: complete response in a patient with Hodgkin's disease refractory to chemotherapy.
    Tepler I; Schwartz G; Parker K; Charette J; Kadin ME; Woodworth TG; Schnipper LE
    Cancer; 1994 Feb; 73(4):1276-85. PubMed ID: 8313331
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Optimizing denileukin diftitox (Ontak) therapy.
    Duvic M; Talpur R
    Future Oncol; 2008 Aug; 4(4):457-69. PubMed ID: 18684057
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Denileukin diftitox: a biotherapeutic paradigm shift in the treatment of lymphoid-derived disorders.
    Turturro F
    Expert Rev Anticancer Ther; 2007 Jan; 7(1):11-7. PubMed ID: 17187516
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diphtheria toxin fusion proteins.
    Foss FM; Saleh MN; Krueger JG; Nichols JC; Murphy JR
    Curr Top Microbiol Immunol; 1998; 234():63-81. PubMed ID: 9670613
    [No Abstract]   [Full Text] [Related]  

  • 29. Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma.
    Attia P; Maker AV; Haworth LR; Rogers-Freezer L; Rosenberg SA
    J Immunother; 2005; 28(6):582-92. PubMed ID: 16224276
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interleukin-1 alpha increases the preferential cytotoxicity of an interleukin-2-diphtheria toxin fusion protein against neoplastic lymphocytes from patients with the Sezary syndrome compared to normal lymphocytes.
    Salard D; Kuzel TM; Samuelson E; Rosen S; Bakouche O
    J Clin Immunol; 1998 May; 18(3):223-34. PubMed ID: 9624582
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma.
    Dang NH; Pro B; Hagemeister FB; Samaniego F; Jones D; Samuels BI; Rodriguez MA; Goy A; Romaguera JE; McLaughlin P; Tong AT; Turturro F; Walker PL; Fayad L
    Br J Haematol; 2007 Feb; 136(3):439-47. PubMed ID: 17233846
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quality-of-life improvements in cutaneous T-cell lymphoma patients treated with denileukin diftitox (ONTAK).
    Duvic M; Kuzel TM; Olsen EA; Martin AG; Foss FM; Kim YH; Heald PW; Bacha P; Nichols J; Liepa A
    Clin Lymphoma; 2002 Mar; 2(4):222-8. PubMed ID: 11970761
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical activity of a cytotoxic fusion protein in the treatment of cutaneous T-cell lymphoma.
    Hesketh P; Caguioa P; Koh H; Dewey H; Facada A; McCaffrey R; Parker K; Nylen P; Woodworth T
    J Clin Oncol; 1993 Sep; 11(9):1682-90. PubMed ID: 8355035
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeted therapies: Denileukin diftitox--a step towards a 'magic bullet' for CTCL.
    Kadin ME; Vonderheid EC
    Nat Rev Clin Oncol; 2010 Aug; 7(8):430-2. PubMed ID: 20668480
    [No Abstract]   [Full Text] [Related]  

  • 35. Phase I trial of a genetically engineered interleukin-2 fusion toxin (DAB486IL-2) as a 6 hour intravenous infusion in patients with hematologic malignancies.
    Platanias LC; Ratain MJ; O'Brien S; Larson RA; Vardiman JW; Shaw JP; Williams SF; Baron JM; Parker K; Woodworth TG
    Leuk Lymphoma; 1994 Jul; 14(3-4):257-62. PubMed ID: 7950914
    [TBL] [Abstract][Full Text] [Related]  

  • 36. DAB(389)IL-2 (denileukin diftitox, ONTAK): review of clinical trials to date.
    Kuzel TM
    Clin Lymphoma; 2000 Nov; 1 Suppl 1():S33-6. PubMed ID: 11707861
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interleukin-2 receptor-directed therapies: antibody-or cytokine-based targeting molecules.
    Strom TB; Kelley VR; Murphy JR; Nichols J; Woodworth TG
    Annu Rev Med; 1993; 44():343-53. PubMed ID: 8476255
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Arginine butyrate increases the cytotoxicity of DAB(389)IL-2 in leukemia and lymphoma cells by upregulation of IL-2Rbeta gene.
    Shao RH; Tian X; Gorgun G; Urbano AG; Foss FM
    Leuk Res; 2002 Dec; 26(12):1077-83. PubMed ID: 12443879
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Denileukin diftitox as novel targeted therapy in non-Hodgkin's lymphoma.
    Walker PL; Dang NH
    Clin J Oncol Nurs; 2004 Apr; 8(2):169-74. PubMed ID: 15108419
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma.
    Olsen E; Duvic M; Frankel A; Kim Y; Martin A; Vonderheid E; Jegasothy B; Wood G; Gordon M; Heald P; Oseroff A; Pinter-Brown L; Bowen G; Kuzel T; Fivenson D; Foss F; Glode M; Molina A; Knobler E; Stewart S; Cooper K; Stevens S; Craig F; Reuben J; Bacha P; Nichols J
    J Clin Oncol; 2001 Jan; 19(2):376-88. PubMed ID: 11208829
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.